1. Home
  2. TG vs ACIU Comparison

TG vs ACIU Comparison

Compare TG & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

N/A

Current Price

$6.59

Market Cap

249.4M

Sector

Industrials

ML Signal

N/A

Logo AC Immune SA

ACIU

AC Immune SA

N/A

Current Price

$2.68

Market Cap

247.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TG
ACIU
Founded
1988
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
249.4M
247.6M
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
TG
ACIU
Price
$6.59
$2.68
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
126.5K
180.6K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
151.06
N/A
EPS
0.34
N/A
Revenue
$800,821,000.00
N/A
Revenue This Year
N/A
$706.75
Revenue Next Year
N/A
$321.13
P/E Ratio
$21.06
N/A
Revenue Growth
8.29
N/A
52 Week Low
$6.25
$2.10
52 Week High
$10.53
$4.00

Technical Indicators

Market Signals
Indicator
TG
ACIU
Relative Strength Index (RSI) 28.77 53.18
Support Level N/A $2.57
Resistance Level $8.12 $3.00
Average True Range (ATR) 0.22 0.12
MACD -0.09 -0.02
Stochastic Oscillator 3.85 35.71

Price Performance

Historical Comparison
TG
ACIU

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: